The majority of sites (66%) showed a decrease in methylation after treatment with CC-486; however, because of the limited number of samples, treatment-induced changes in the CpG site methylation did not reach statistical significance (Additional file 2 : Fig S1).
← all excerpts
A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence.
1
—
—